1400285-22-4Relevant articles and documents
Structure-based design of orally bioavailable 1 h -Pyrrolo[3,2- C ]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)
Naud, Sébastien,Westwood, Isaac M.,Faisal, Amir,Sheldrake, Peter,Bavetsias, Vassilios,Atrash, Butrus,Cheung, Kwai-Ming J.,Liu, Manjuan,Hayes, Angela,Schmitt, Jessica,Wood, Amy,Choi, Vanessa,Boxall, Kathy,Mak, Grace,Gurden, Mark,Valenti, Melanie,De Haven Brandon, Alexis,Henley, Alan,Baker, Ross,McAndrew, Craig,Matijssen, Berry,Burke, Rosemary,Hoelder, Swen,Eccles, Suzanne A.,Raynaud, Florence I.,Linardopoulos, Spiros,Van Montfort, Rob L. M.,Blagg, Julian
, p. 10045 - 10065 (2014/01/17)
The protein kinase MPS1 is a crucial component of the spindle assembly checkpoint signal and is aberrantly overexpressed in many human cancers. MPS1 is one of the top 25 genes overexpressed in tumors with chromosomal instability and aneuploidy. PTEN-defic
PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS
-
Page/Page column 118; 139, (2012/10/07)
The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as "PPA derivatives"), particularly 1H-pyrrolo[3,2-c]pyridine-6- amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 – also known as TTK) kinases either directly or indirectly via interaction with the Mps kinase itself. In particular, the present invention relates to PPA derivatives for use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of the PPA derivatives, and pharmaceutical compositions comprising them. Formula (I)